Immunic, Inc.
IMUXImmunic, Inc. in brief
Immunic, Inc. is a listed company in the Biotechnology industry, based in the USA. Its market value was $121 M on 28 October 2026, which makes it the 18,073rd largest listed company in the world and the 3,422nd largest in the USA on this site. Erik Lundgren is its chief executive. Its shares trade under the symbol IMUX (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Immunic, Inc.
Immunic is a Clinical Stage Biopharmaceutical company with a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. It is having 26 employees as on 2020. The headquarters is in USA.
Immunic, Inc. timeline
- 2004
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2014
- 🔔· approximateInitial public offering on Nasdaq
- 2019
- ✎Renamed Immunic, Inc.Formerly Vital Therapies Inc.
Events of Immunic, Inc. from SEC EDGAR and the company record. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #3,717 (Jan 2020) · #2,905 (Jan 2021) · #3,633 (Jan 2022) · #4,683 (Dec 2022) · #4,181 (Jul 2023) · #3,936 (Jan 2024) · #1,796 (Mar 2026) · #3,051 (Aug 2026) · #3,452 (Oct 2026) · #3,425 (Oct 2026)
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | — | — | $-103M | $-97M | — |
| Dec 2024 | — | — | $-98M | $-101M | — |
| Dec 2023 | — | — | $-99M | $-94M | — |
| Dec 2022 | — | — | $-119M | $-120M | — |
| Dec 2021 | — | — | $-92M | $-93M | — |
| Dec 2020 | — | — | $-49M | $-44M | — |
| Dec 2019 | — | — | $-37M | $-35M | — |
| Dec 2018 | — | — | $-12M | $-12M | — |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-86M | $0M | $-86M | $-0.62 | $0.00 |
| Dec 2024 | $-85M | $0M | $-85M | $-1.00 | $0.00 |
| Dec 2023 | $-71M | $0M | $-71M | $-2.11 | $0.00 |
| Dec 2022 | $-65M | $0M | $-65M | $-3.78 | $0.00 |
| Dec 2021 | $-83M | $0M | $-83M | $-3.93 | $0.00 |
| Dec 2020 | $-46M | $0M | $-46M | $-2.81 | $0.00 |
| Dec 2019 | $-29M | $0M | $-29M | $-4.52 | $0.00 |
| Dec 2018 | $-10M | $0M | $-10M | $-13.63 | $0.00 |
Quarterly results
Latest quarter to Sep 2026: revenue —, net income $-42M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Jun 2026.
SEC filings
- Nov 5, 20268-KCurrent reportRegulation FD disclosure
- Sep 11, 20268-KCurrent reportDirectors or officers changed
- Sep 9, 20268-KCurrent reportRegulation FD disclosure
- Aug 11, 20268-KCurrent reportResults of operations · Directors or officers changed · Regulation FD disclosure
- Aug 11, 202610-QQuarterly report · period to Jun 2026
- Jul 14, 20268-KCurrent reportRegulation FD disclosure
- Jul 6, 20268-KCurrent reportDirectors or officers changed
- Jun 29, 20268-KCurrent reportDirectors or officers changed · Shareholder vote
- May 29, 2026DEF 14AProxy statement
- May 28, 20268-KCurrent reportRegulation FD disclosure
- May 27, 20268-KCurrent reportDirectors or officers changed · Regulation FD disclosure
- May 19, 20268-KCurrent reportDirectors or officers changed · Regulation FD disclosure
Official filings of Immunic, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- —
- Operating income
- $-103 M
- Net income
- $-97 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $24 M
- Total liabilities
- $31 M
- Total equity
- $-7 M
As of December-2025
Top 78 institutional investors in Immunic, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Aberdeen Group plc | 1,090,427 | +266,034 (+32.27%) | 7.99% | $10 M | Nov 10, 2026 |
| 2 | BVF Inc/il | 765,295 | 0 (0.00%) | 5.61% | $7 M | Nov 16, 2026 |
| 3 | Morgan Stanley | 704,244 | +680,496 (+2865.49%) | 5.16% | $7 M | Nov 13, 2026 |
| 4 | Seven Fleet Capital Management LP | 687,240 | New | 5.04% | $6 M | Nov 16, 2026 |
| 5 | Millennium Management LLC | 681,024 | -59,323 (-8.01%) | 4.99% | $6 M | Nov 16, 2026 |
| 6 | Avidity Partners Management LP | 669,941 | 0 (0.00%) | 4.91% | $6 M | Nov 16, 2026 |
| 7 | Braidwell LP | 645,110 | +100 (+0.02%) | 4.73% | $6 M | Nov 16, 2026 |
| 8 | Laurion Capital Management LP | 610,326 | 0 (0.00%) | 4.47% | $6 M | Oct 30, 2026 |
| 9 | Vanguard Capital Management LLC | 571,561 | 0 (0.00%) | 4.19% | $5 M | Nov 13, 2026 |
| 10 | Orbimed Advisors LLC | 475,804 | New | 3.49% | $4 M | Nov 16, 2026 |
| 11 | Woodline Partners LP | 472,000 | +472 (+0.10%) | 3.46% | $4 M | Nov 16, 2026 |
| 12 | Omega Fund Management, LLC | 430,180 | New | 3.15% | $4 M | Nov 16, 2026 |
| 13 | Marshall Wace, LLP | 359,319 | +254,503 (+242.81%) | 2.63% | $3 M | Nov 13, 2026 |
| 14 | Nantahala Capital Management, LLC | 250,646 | -250,646 (-50.00%) | 1.84% | $2 M | Nov 13, 2026 |
| 15 | Propel Bio Management, LLC | 236,734 | -88,288 (-27.16%) | 1.74% | $2 M | Nov 13, 2026 |
| 16 | Jane Street Group, LLC | 214,163 | +124,476 (+138.79%) | 1.57% | $2 M | Nov 12, 2026 |
| 17 | UBS Group AG | 183,629 | +7,873 (+4.48%) | 1.35% | $2 M | Nov 10, 2026 |
| 18 | Ikarian Capital, LLC | 182,464 | +115,000 (+170.46%) | 1.34% | $2 M | Nov 16, 2026 |
| 19 | Geode Capital Management, LLC | 172,142 | +1,467 (+0.86%) | 1.26% | $2 M | Nov 6, 2026 |
| 20 | Qube Research & Technologies Ltd | 147,577 | New | 1.08% | $1 M | Nov 13, 2026 |
| 21 | Adage Capital Partners GP, L.L.C. | 139,860 | 0 (0.00%) | 1.02% | $1 M | Nov 16, 2026 |
| 22 | Citadel Advisors LLC | 129,654 | +108,034 (+499.69%) | 0.95% | $1 M | Nov 16, 2026 |
| 23 | BlackRock, Inc. | 126,222 | -6,569 (-4.95%) | 0.93% | $1 M | Nov 13, 2026 |
| 24 | Susquehanna International Group, LLP | 110,548 | +19,658 (+21.63%) | 0.81% | $1 M | Nov 16, 2026 |
| 25 | State Street Corp | 83,859 | +22,600 (+36.89%) | 0.61% | $1 M | Nov 12, 2026 |
Show all 78: investors 26 to 78
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Vanguard Fiduciary Trust Co | 82,029 | 0 (0.00%) | 0.60% | $1 M | Nov 13, 2026 |
| 27 | Renaissance Technologies LLC | 71,330 | New | 0.52% | $1 M | Nov 12, 2026 |
| 28 | 683 Capital Management, LLC | 65,000 | -82,245 (-55.86%) | 0.48% | $1 M | Nov 16, 2026 |
| 29 | Boothbay Fund Management, LLC | 46,820 | +33,763 (+258.58%) | 0.34% | $0 M | Nov 16, 2026 |
| 30 | Schonfeld Strategic Advisors LLC | 45,599 | New | 0.33% | $0 M | Nov 16, 2026 |
| 31 | Squarepoint Ops LLC | 42,283 | New | 0.31% | $0 M | Nov 9, 2026 |
| 32 | Two Sigma Investments, LP | 37,671 | New | 0.28% | $0 M | Nov 16, 2026 |
| 33 | Engineers Gate Manager LP | 36,600 | New | 0.27% | $0 M | Nov 16, 2026 |
| 34 | Quadrature Capital Ltd | 31,058 | -6,728 (-17.81%) | 0.23% | $0 M | Nov 13, 2026 |
| 35 | Simplify Asset Management Inc. | 30,725 | 0 (0.00%) | 0.23% | $0 M | Oct 27, 2026 |
| 36 | Northern Trust Corp | 30,720 | 0 (0.00%) | 0.23% | $0 M | Nov 16, 2026 |
| 37 | Birchview Capital, LP | 21,917 | New | 0.16% | $0 M | Nov 13, 2026 |
| 38 | Axq Capital, LP | 21,009 | New | 0.15% | $0 M | Nov 12, 2026 |
| 39 | Graham Capital Management, L.P. | 19,722 | New | 0.14% | $0 M | Nov 16, 2026 |
| 40 | Alps Advisors Inc | 17,694 | +3,870 (+27.99%) | 0.13% | $0 M | Nov 3, 2026 |
| 41 | American Century Companies Inc | 17,523 | New | 0.13% | $0 M | Nov 12, 2026 |
| 42 | LPL Financial LLC | 17,012 | -429 (-2.46%) | 0.12% | $0 M | Nov 6, 2026 |
| 43 | Catalyst Funds Management Pty Ltd | 16,339 | New | 0.12% | $0 M | Nov 12, 2026 |
| 44 | XTX Topco Ltd | 15,240 | New | 0.11% | $0 M | Nov 16, 2026 |
| 45 | Spark Investment Management LLC | 11,600 | New | 0.09% | $0 M | Nov 13, 2026 |
| 46 | MML Investors Services, LLC | 11,487 | -3,175 (-21.65%) | 0.08% | $0 M | Nov 13, 2026 |
| 47 | Point72 Asset Management, L.P. | 10,806 | 0 (0.00%) | 0.08% | $0 M | Nov 16, 2026 |
| 48 | Prelude Capital Management, LLC | 10,779 | New | 0.08% | $0 M | Nov 16, 2026 |
| 49 | Bank Of America Corp /de/ | 10,472 | New | 0.08% | $0 M | Nov 16, 2026 |
| 50 | Strategies Wealth Advisors, LLC | 10,000 | 0 (0.00%) | 0.07% | $0 M | Nov 13, 2026 |
| 51 | China Universal Asset Management Co., Ltd. | 7,800 | +1,400 (+21.88%) | 0.06% | $0 M | Oct 28, 2026 |
| 52 | Simplex Trading, LLC | 6,667 | New | 0.05% | $0 M | Nov 4, 2026 |
| 53 | Vanguard Global Advisers, LLC | 6,160 | +2,974 (+93.35%) | 0.05% | $0 M | Nov 13, 2026 |
| 54 | Walleye Capital LLC | 5,008 | New | 0.04% | $0 M | Nov 13, 2026 |
| 55 | Barclays PLC | 4,025 | +3,531 (+714.78%) | 0.03% | $0 M | Nov 6, 2026 |
| 56 | Acadian Asset Management LLC | 3,549 | New | 0.03% | $0 M | Nov 9, 2026 |
| 57 | Royal Bank Of Canada | 2,470 | +1,470 (+147.00%) | 0.02% | $0 M | Nov 16, 2026 |
| 58 | Tower Research Capital LLC (TRC) | 2,134 | New | 0.02% | $0 M | Nov 16, 2026 |
| 59 | Citigroup Inc | 1,517 | -3,052 (-66.80%) | 0.01% | $0 M | Nov 4, 2026 |
| 60 | Providence Capital Advisors, LLC | 682 | 0 (0.00%) | 0.01% | $0 M | Nov 13, 2026 |
| 61 | SBI Securities Co., Ltd. | 515 | +142 (+38.07%) | 0.00% | $0 M | Oct 22, 2026 |
| 62 | Pinnacle Financial Group, Inc. | 440 | — | 0.00% | $0 M | Nov 16, 2026 |
| 63 | Jones Financial Companies Lllp | 355 | New | 0.00% | $0 M | Nov 13, 2026 |
| 64 | FMR LLC | 337 | +209 (+163.28%) | 0.00% | $0 M | Nov 10, 2026 |
| 65 | Northwestern Mutual Wealth Management Co | 150 | 0 (0.00%) | 0.00% | $0 M | Nov 13, 2026 |
| 66 | Rockefeller Capital Management L.P. | 100 | 0 (0.00%) | 0.00% | $0 M | Nov 13, 2026 |
| 67 | Allworth Financial LP | 84 | 0 (0.00%) | 0.00% | $0 M | Nov 17, 2026 |
| 68 | Nova Financial LLC | 80 | -100 (-55.56%) | 0.00% | $0 M | Nov 4, 2026 |
| 69 | Rialto Wealth Management, LLC | 49 | New | 0.00% | $0 M | Nov 16, 2026 |
| 70 | Cassaday & Co Wealth Management LLC | 40 | New | 0.00% | $0 M | Oct 27, 2026 |
| 71 | Jpmorgan Chase & Co | 38 | 0 (0.00%) | 0.00% | $0 M | Nov 12, 2026 |
| 72 | Caitong International Asset Management Co., Ltd | 18 | +16 (+800.00%) | 0.00% | $0 M | Oct 29, 2026 |
| 73 | Caldwell Sutter Capital, Inc. | 10 | 0 (0.00%) | 0.00% | $0 M | Nov 9, 2026 |
| 74 | Aster Capital Management (DIFC) Ltd | 3 | New | 0.00% | $0 M | Nov 12, 2026 |
| 75 | Wells Fargo & Company/mn | 2 | -85 (-97.70%) | 0.00% | $0 M | Nov 16, 2026 |
| 76 | Danske Bank A/s | 2 | 0 (0.00%) | 0.00% | $0 M | Nov 9, 2026 |
| 77 | Smartleaf Asset Management LLC | 2 | New | 0.00% | $0 M | Nov 10, 2026 |
| 78 | Robinhood Markets, Inc. | 1 | — | 0.00% | $0 M | Nov 18, 2026 |
Mutual funds holding Immunic, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 abrdn Healthcare Investorsabrdn Inc. | 473,877 | $7 M | 3.5% | 0.53% | −0.0% | Jun 30, 2026 |
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 399,088 | $6 M | 2.9% | <0.01% | +8.9% | Jun 30, 2026 |
| 🇺🇸 abrdn Life Sciences Investorsabrdn Inc. | 302,891 | $5 M | 2.2% | 0.68% | −0.0% | Jun 30, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 159,248 | $2 M | 1.2% | <0.01% | +17% | Jun 30, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 63,010 | $1 M | 0.46% | <0.01% | −2.1% | May 31, 2026 |
| 🇺🇸 abrdn World Healthcare Fundabrdn Inc. | 47,625 | $1 M | 0.35% | 0.13% | −0.0% | Jun 30, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 46,243 | $1 M | 0.34% | 0.05% | +52% | Jun 30, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 29,253 | $0 M | 0.21% | <0.01% | −0.0% | May 31, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 17,808 | $0 M | 0.13% | <0.01% | +14% | May 31, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 9,839 | $0 M | 0.07% | <0.01% | +152% | May 31, 2026 |
| 🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc. | 8,500 | $0 M | 0.06% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Fidelity ZERO Total Market Index FundFidelity Management & Research Company LLC | 8,037 | $0 M | 0.06% | <0.01% | +30% | Jul 31, 2026 |
| 🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc. | 6,993 | $0 M | 0.05% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 6,232 | $0 M | 0.05% | <0.01% | +46% | Jun 30, 2026 |
| 🇺🇸 Fidelity ZERO Extended Market Index FundFidelity Management & Research Company LLC | 5,154 | $0 M | 0.04% | <0.01% | +23% | Jul 31, 2026 |
| 🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC | 3,121 | $0 M | 0.02% | 0.02% | +47% | Jun 30, 2026 |
| 🇺🇸 Fidelity Flex Small Cap Index FundFidelity Management & Research Company LLC | 2,207 | $0 M | 0.02% | <0.01% | +18% | Jul 31, 2026 |
| 🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc. | 1,556 | $0 M | 0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 VIP Extended Market Index PortfolioFidelity Management & Research Company LLC | 866 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 VIP Total Market Index PortfolioFidelity Management & Research Company LLC | 297 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC | 277 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 21 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Immunic, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Duane NashExecutive Chairman, Director | Buy | +20,000 | $0.830 | $17 K | 36,032 | Form 4 |
| filed | Jason TardioPresident and COO | Buyamended | +12,512 | $0.790 | $10 K | 12,512 | Form 4/A |
| filed | Jason TardioPresident and COO | Buy | +12,512 | $0.790 | $10 K | 12,512 | Form 4 |
| filed | Joerg NeermannDirector | Buy | +30,000 | $0.760 | $23 K | 200,000 | Form 4 |
| filed | Daniel VittCEO and Director, Director | Buyamended | +15,000 | $0.770 | $12 K | 29,000 | Form 4/A |
| filed | Daniel VittCEO and Director, Director | Buy | +15,000 | $0.770 | $12 K | 29,000 | Form 4 |
| filed | Joerg NeermannDirector | Buy | +70,000 | $0.770 | $54 K | 170,000 | Form 4 |
| filed | Richard Alan RudickDirector | Buy | +143,075 | $0.700 | $100 K | 230,375 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Immunic, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 1-for-40 reverse split
| Dividend, quarter | Per share | |
|---|---|---|
| Q1 2026 | $0.000 | |
| Q1 2025 | $0.000 | |
| Q1 2024 | $0.000 | |
| Q1 2023 | $0.000 | |
| Q1 2022 | $0.000 | |
| Q1 2021 | $0.000 | |
| Q1 2020 | $0.000 |
Trading halts
- 2026-04-24 23:50 UTC, code T3, resumed 13:00 UTC
Fails to deliver
- : 3,875 shares at $7.61
- : 465 shares at $6.97
- : 13 shares at $6.66
- : 13 shares at $6.89
- : 557 shares at $7.95
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Immunic, Inc. scorecard#
Passes 0 of the 13 checks that could be worked out. Fiscal year 2025; market cap of Oct 28, 2026.
Valuation0 of 4
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✗Price to book below its peers' medianNo price to bookShareholders' equity is negative.
- –Price to sales below its peers' medianNo Price to sales on file.
- ✗Free cash flow yield above 5%-71.1%Free cash flow is -71.1% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth0 of 2
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-0.62 vs -1.00Diluted EPS -0.62 in fiscal 2025 against -1.00 the year before (report's currency).
- ✗Net income higher than five years earlier-$97 M-$97 M in fiscal 2025 against -$44 M in 2020.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 2
- ✗Profitable in the newest year-$97 MNet income -$97 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- –Operating margin above its peers' medianNo operating margin on file.
- –Return on equity above 15%No return on equity (equity missing or negative).
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health0 of 2
- ✗Short-term assets cover short-term liabilities0.8×Current ratio 0.75 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returns0 of 3
- ✗Pays a dividendNoNo dividends in fiscal 2025.
- ✗Dividend per share raised five years in a row0 of 5Dividend per share raised in 0 of the five years to fiscal 2025.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year55.4%Diluted shares up 55.4% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Immunic, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Research and development | 82+2.4%— | 80−3.8%— | 83+16.8%— | 71+16.6%— | 61+58.2%— | 39+71.6%— | 23+135%— | 9.6r25−75.6%— | 39+30.9%— | 30—— | |
| General and administrative | 21+18.0%— | 18+12.5%— | 16+4.9%— | 15+14.8%— | 13+28.7%— | 10−28.8%— | 15+504%— | 2.4r14−82.0%— | 13+18.7%— | 11—— | |
| Operating expenses | 103+5.3%— | 98−1.2%— | 99−17.0%— | 119+30.4%— | 92+87.2%— | 49+32.2%— | 37+209%— | 12r42−77.2%— | 53+27.6%— | 41—— | |
| Operating income | −103—— | −98—— | −99—— | −119—— | −92—— | −49—— | −37—— | −12r−42—— | −53—— | −41—— | |
| Interest and finance income | 1.0−69.3%— | 3.4+10.2%— | 3.1+195%— | 1.0+1477%— | 0.1+13.8%— | 0.1−45.8%— | 0.1−79.5%— | 0.5−19.8%— | 0.7+129%— | 0.3—— | |
| Provision for credit losses | 0.5+112%— | 0.2—— | — | — | — | — | — | — | — | — | |
| Other non-operating income (expense) | 6.1—— | −2.5−144%— | 5.6—— | −0.9—— | −1.3−126%— | 5.0+136%— | 2.1+361%— | 0.5r0.5−21.1%— | 0.6+94.3%— | 0.3—— | |
| Income before tax | — | — | — | — | — | — | — | −41—— | −52—— | −41—— | |
| Income tax | 0—— | — | — | — | — | — | — | — | — | — | |
| Net income including minority interests | — | — | — | — | — | — | — | — | −52—— | −41—— | |
| Net income attributable to shareholders | −97—— | −101—— | −94—— | −120—— | −93—— | −44—— | −35—— | −12r−41—— | −52—— | −41—— | |
| Earnings per share, basic | -0.62—— | -1.00—— | -2.11—— | -3.78—— | -3.93—— | -2.81—— | -4.52—— | -13.63r-0.98—— | -1.31—— | -1.31—— | |
| Earnings per share, diluted | -0.62—— | -1.00—— | -2.11—— | -3.78—— | -3.93—— | -2.81—— | -4.52—— | -13.63r-0.98—— | -1.31—— | -1.31—— | |
| Shares, weighted average (basic) | 156+55.4%— | 100+126%— | 44+39.3%— | 32+34.5%— | 24+51.0%— | 16—— | — | — | — | — | |
| Shares, weighted average (diluted) | 156+55.4%— | 100+126%— | 44+39.3%— | 32+34.5%— | 24+51.0%— | 16+103%— | 7.7+812%— | 0.8r42−97.9%— | 40+27.0%— | 31—— | |
| Dividends per share | 0.00—— | 0.00—— | 0.00—— | 0.00—— | 0.00—— | 0.00—— | 0.00—— | 0.00—— | — | — | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 15−56.6%64.4% | 36−23.6%87.3% | 47−56.3%86.0% | 107+22.9%83.6% | 87−31.8%62.4% | 127+334%75.9% | 29+125%44.5% | 13r13−77.0%97.8% | 57−5.2%94.2% | 60—93.7% | |
| Other current assets | 0.8r1.2−25.1%3.5% | 1.1r1.1+3.7%2.7% | 1.1r1.1−12.7%2.0% | 1.2+9.2%1.0% | 1.1−9.1%0.8% | 1.2+55.0%0.7% | 0.8r0.8+1071%1.2% | 0.1r0.9−94.4%0.5% | 1.2−17.1%2.0% | 1.5—2.3% | |
| Current assets | 23−41.9%95.1% | 39−25.1%96.2% | 53−58.3%96.7% | 126+19.9%98.5% | 105−21.5%75.5% | 134+315%79.7% | 32+142%48.9% | 13r14−77.1%99.7% | 58−5.4%96.3% | 61—96.0% | |
| Property, plant and equipment | 0.6+11.6%2.5% | 0.5+17.0%1.3% | 0.5+58.5%0.9% | 0.3+93.4%0.2% | 0.2−25.1%0.1% | 0.2+154%0.1% | 0.1+100%0.1% | 0.0r0.7−98.1%0.3% | 2.2−14.0%3.6% | 2.5—3.9% | |
| Right-of-use (leased) assets | 0.6−42.0%2.4% | 1.0−23.7%2.4% | 1.3−16.3%2.4% | 1.6+63.7%1.2% | 0.9+5.2%0.7% | 0.9+42.3%0.5% | 0.6—1.0% | — | — | — | |
| Goodwill | — | — | — | 0−100%0.0% | 330.0%23.7% | 330.0%19.6% | 33—50.0% | 0—0.0% | — | — | |
| Total assets | 24−41.1%100% | 41−24.7%100% | 54−57.5%100% | 128−8.2%100% | 139−17.1%100% | 168+155%100% | 66+393%100% | 13r15−77.9%100% | 60−5.7%100% | 64—100% | |
| Accounts payable | 10+29.2%42.2% | 7.8+53.9%19.2% | 5.1+19.1%9.4% | 4.3+14.3%3.4% | 3.7+1.2%2.7% | 3.7+52.7%2.2% | 2.4+73.1%3.7% | 1.4r0.3+33.5%10.5% | 1.0+34.5%1.7% | 0.8—1.2% | |
| Current liabilities | 31+38.1%127% | 22−10.3%54.3% | 25+89.1%45.5% | 13+14.7%10.2% | 11+35.8%8.2% | 8.4+18.7%5.0% | 7.1+268%10.7% | 1.9r2.5−81.3%14.4% | 10+87.6%17.0% | 5.5—8.6% | |
| Lease liabilities (non-current) | 0.1−59.5%0.4% | 0.3−58.7%0.6% | 0.6−35.6%1.2% | 1.0+69.9%0.8% | 0.6−14.0%0.4% | 0.7+30.6%0.4% | 0.5+1168%0.8% | 0.0−30.5%0.3% | 0.1—0.1% | — | |
| Non-current liabilities | 0.1−59.5%0.4% | 0.3−58.7%0.6% | 0.6−35.6%1.2% | 1.0+69.9%0.8% | 0.6−14.0%0.4% | 0.7+30.6%0.4% | 0.5—0.8% | 0r0.0−100%0.0% | 0.1−41.0%0.1% | 0.1—0.2% | |
| Total liabilities | 31+36.9%128% | 22−11.5%54.9% | 25+80.3%46.7% | 14+17.4%11.0% | 12+32.1%8.6% | 9.1+19.5%5.4% | 7.6+295%11.5% | 1.9—14.4% | — | — | |
| Retained earnings | −609—−2530% | −511—−1251% | −411—−757% | −317—−248% | −197—−142% | −104—−61.9% | −60—−90.8% | −25r−337—−187% | −296—−490% | −244—−381% | |
| Shareholders' equity | −6.7−136%−27.7% | 18−36.3%45.1% | 29−74.6%53.3% | 114−10.6%89.0% | 127−19.9%91.4% | 159+172%94.6% | 58—88.5% | −26r12—−193% | −13r50−123%−22.1% | 58—91.3% | |
| Total liabilities and equity | 24−41.1%100% | 41−24.7%100% | 54−57.5%100% | 128−8.2%100% | 139−17.1%100% | 168+155%100% | 66+393%100% | 13r15−77.9%100% | 60−5.7%100% | 64—100% | |
| Shares outstanding | 16r90−82.4%— | 90+99.5%— | 45+14.9%— | 39+49.3%— | 26+24.4%— | 21+97.0%— | 11+1169%— | 0.8r42−98.0%— | 42+31.8%— | 32—— | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | 0.2+25.4%— | 0.1+20.7%— | 0.1+44.2%— | 0.1−9.4%— | 0.1+118%— | 0.0−22.0%— | 0.1+233%— | 0.0r0.7−98.5%— | 1.0−44.8%— | 1.8—— | |
| Share-based compensation | 8.9+3.9%— | 8.5+20.1%— | 7.1−10.4%— | 7.9+33.3%— | 5.9+117%— | 2.7−57.8%— | 6.5—— | 0r3.7−100%— | 5.5+17.1%— | 4.7—— | |
| Cash from operating activities | −86—— | −85—— | −71—— | −65—— | −83—— | −46—— | −29—— | −9.7r−43—— | −40—— | −36—— | |
| Capital expenditure | −0.2—— | −0.3—— | −0.3—— | −0.1—— | −0.1—— | −0.1—— | −0.1—— | −0.0r−0.6—— | −0.7—— | −0.6—— | |
| Intangible assets bought | — | — | — | — | — | 0—— | −0.1—— | — | — | — | |
| Cash from investing activities | −0.2—— | −0.3−103%— | 9.5—— | −9.7—— | −0.1—— | −0.1−101%— | 11—— | −0.0r−0.4—— | −0.7—— | −0.0—— | |
| Shares issued | 0−100%— | 0.2−77.6%— | 0.9—— | — | — | — | 0−100%— | 19r0−49.3%— | 38+208%— | 12—— | |
| Cash from financing activities | 66−12.0%— | 75+7116%— | 1.0−98.9%— | 96+124%— | 43−70.3%— | 144+314%— | 35+81.2%— | 19r0.0−49.3%— | 38+207%— | 12—— | |
| Exchange-rate effect on cash | 0.2—— | −0.5−297%— | 0.3—— | −1.0—— | −0.1—— | −0.1—— | −0.6—— | −0.9—— | — | — | |
| Change in cash | −20—— | −11—— | −60−402%— | 20—— | −41−141%— | 98+502%— | 16+90.2%— | 8.6r−44—— | −3.1—— | −23—— | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Research and development | 95+11.9%— | 24+19.7%— | 26+21.3%— | 26+19.0%— | 19*−11.8%— | 20−6.4%— | 21+16.6%— | 22+14.9%— | 22*+12.1%— | 21—— | 18—— | 19—— | 19*—— | |
| General and administrative | 41+93.7%— | 19+225%— | 9.4+64.4%— | 7.6+43.8%— | 4.3*+6.1%— | 6.0+37.3%— | 5.7+27.2%— | 5.3+2.9%— | 4.0*−2.0%— | 4.4—— | 4.5—— | 5.1—— | 4.1*—— | |
| Operating expenses | 135+28.2%— | 43+66.8%— | 35+30.4%— | 33+23.9%— | 23*−9.0%— | 26+1.0%— | 27+18.7%— | 27+12.3%— | 26*+9.6%— | 26—— | 23—— | 24—— | 23*—— | |
| Operating income | −135—— | −43—— | −35—— | −33—— | −23*—— | −26—— | −27—— | −27—— | −26*—— | −26—— | −23—— | −24—— | −23*—— | |
| Interest and finance income | 3.3+162%— | 1.1+161%— | 1.3+434%— | 0.8+315%— | 0.2*−54.1%— | 0.4−46.0%— | 0.2−75.9%— | 0.2−84.6%— | 0.4*−20.7%— | 0.8—— | 1.0—— | 1.2—— | 0.5*—— | |
| Provision for credit losses | 0.8+2063%— | 0.1*+16.7%— | 0.2*+280%— | 0.2+185%— | 0.3*—— | 0.0*+269%— | 0.1*−66.5%— | 0.1−70.2%— | −0.1*—— | 0.0*—— | 0.2*—— | 0.2—— | — | |
| Other non-operating income (expense) | 7.0+180%— | 1.1+156%— | 1.2+367%— | 0.6−52.1%— | 4.0*+783%— | 0.4−69.5%— | 0.3−81.7%— | 1.4—— | 0.5*−74.8%— | 1.4—— | 1.4—— | −5.7—— | 1.8*—— | |
| Net income attributable to shareholders | −128—— | −42—— | −34—— | −33—— | −19*—— | −26—— | −27—— | −25—— | −25*—— | −24—— | −21—— | −30—— | −22*—— | |
| Earnings per share, basic | — | -0.99—— | -0.80—— | -1.08—— | — | -1.32r-0.13—— | -2.03r-0.20—— | -2.51r-0.25—— | — | -0.24—— | -0.21—— | -0.30—— | — | |
| Earnings per share, diluted | — | -0.99—— | -0.80—— | -1.08—— | — | -1.32r-0.13—— | -2.03r-0.20—— | -2.51r-0.25—— | — | -0.24—— | -0.21—— | -0.30—— | — | |
| Shares, weighted average (basic) | 43+121%— | 43+121%— | 43+222%— | 30+197%— | — | 19r194−80.9%— | 13r132−86.9%— | 10r101−89.6%— | — | 101—— | 101—— | 97—— | — | |
| Shares, weighted average (diluted) | 43+121%— | 43+121%— | 43+222%— | 30+197%— | — | 19r194−80.9%— | 13r132−86.9%— | 10r101−89.6%— | — | 101—— | 101—— | 97—— | — | |
| Dividends per share | — | — | — | 0.00—— | — | — | — | 0.00—— | — | — | — | 0.00—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 132—96.7% | 132+276%96.7% | 155+180%97.4% | 187+1205%98.4% | 15−56.6%64.4% | 35−40.5%86.3% | 55−30.6%90.0% | 14−85.3%69.7% | 36−23.6%87.3% | 59—91.2% | 80—92.1% | 97—93.4% | 47—86.0% | |
| Other current assets | 0.8—0.6% | 0.8+2.9%0.6% | 0.9−1.3%0.5% | 1.1−15.6%0.6% | 0.8r1.2−25.1%3.5% | 0.8+8.1%2.0% | 0.9−18.5%1.4% | 1.3+15.0%6.1% | 1.1r1.1+3.7%2.7% | 0.8—1.2% | 1.1—1.2% | 1.1—1.0% | 1.1r1.1—2.0% | |
| Current assets | 135—99.0% | 135+244%99.0% | 158+164%99.2% | 189+895%99.5% | 23−41.9%95.1% | 39−37.9%96.5% | 60−29.6%97.4% | 19−81.5%92.5% | 39−25.1%96.2% | 63—97.7% | 85—98.3% | 103—98.5% | 53—96.7% | |
| Property, plant and equipment | 0.8—0.6% | 0.8+30.0%0.6% | 0.8+26.0%0.5% | 0.6−1.0%0.3% | 0.6+11.6%2.5% | 0.6+3.6%1.6% | 0.6+4.6%1.0% | 0.6+29.4%2.8% | 0.5+17.0%1.3% | 0.6—1.0% | 0.6—0.7% | 0.4—0.4% | 0.5—0.9% | |
| Right-of-use (leased) assets | 0.5—0.4% | 0.5−36.3%0.4% | 0.6−42.1%0.4% | 0.4−56.9%0.2% | 0.6−42.0%2.4% | 0.8−9.9%1.9% | 1.0+5.1%1.6% | 1.0−11.8%4.7% | 1.0−23.7%2.4% | 0.9—1.4% | 0.9—1.1% | 1.1—1.1% | 1.3—2.4% | |
| Total assets | 136—100% | 136+235%100% | 159+159%100% | 190+825%100% | 24−41.1%100% | 41−37.1%100% | 61−29.0%100% | 21−80.3%100% | 41−24.7%100% | 65—100% | 86—100% | 104—100% | 54—100% | |
| Accounts payable | 10—7.4% | 10+27.8%7.4% | 13+60.5%8.0% | 11+83.2%5.8% | 10+29.2%42.2% | 7.9+31.0%19.5% | 7.9−0.0%12.8% | 6.0−11.2%29.3% | 7.8+53.9%19.2% | 6.0—9.3% | 7.9—9.1% | 6.8—6.5% | 5.1—9.4% | |
| Current liabilities | 32—23.1% | 32+4.9%23.1% | 31+14.5%19.6% | 38+49.9%20.2% | 31+38.1%127% | 30+28.8%73.9% | 27+20.4%44.5% | 26+27.0%125% | 22−10.3%54.3% | 23—36.1% | 23—26.2% | 20—19.3% | 25—45.5% | |
| Lease liabilities (non-current) | — | — | 0.3+60.0%0.2% | 0.1−30.5%0.1% | 0.1−59.5%0.4% | 0.1−32.3%0.3% | 0.2−14.9%0.3% | 0.2−51.5%1.0% | 0.3−58.7%0.6% | 0.2—0.3% | 0.2—0.3% | 0.4—0.4% | 0.6—1.2% | |
| Non-current liabilities | 0.4—0.3% | 0.4+217%0.3% | 0.3+60.0%0.2% | 0.1−30.5%0.1% | 0.1−59.5%0.4% | 0.1−32.3%0.3% | 0.2−14.9%0.3% | 0.2−51.5%1.0% | 0.3−58.7%0.6% | 0.2—0.3% | 0.2—0.3% | 0.4—0.4% | 0.6—1.2% | |
| Total liabilities | 32—23.4% | 32+5.8%23.4% | 32+14.8%19.8% | 39+49.2%20.3% | 31+36.9%128% | 30+28.3%74.2% | 28+20.1%44.8% | 26+25.4%126% | 22−11.5%54.9% | 24—36.4% | 23—26.5% | 21—19.8% | 25—46.7% | |
| Retained earnings | −718—−526% | −718—−526% | −675—−424% | −641—−338% | −609—−2530% | −589—−1448% | −564—−918% | −537—−2617% | −511—−1251% | −486—−751% | −462—−534% | −440—−423% | −411—−757% | |
| Shareholders' equity | 104—76.6% | 104+895%76.6% | 128r128+276%80.2% | 151r151—79.7% | −6.7−136%−27.7% | 10−74.5%25.8% | 34−46.7%55.2% | −5.3−106%−25.8% | 18−36.3%45.1% | 41—63.6% | 64—73.5% | 84—80.2% | 29—53.3% | |
| Total liabilities and equity | 136—100% | 136+235%100% | 159+159%100% | 190+825%100% | 24−41.1%100% | 41−37.1%100% | 61−29.0%100% | 21−80.3%100% | 41−24.7%100% | 65—100% | 86—100% | 104—100% | 54—100% | |
| Shares outstanding | 12—— | 12−87.8%— | 14−86.2%— | 14−84.9%— | 16r90−82.4%— | 99+9.5%— | 99+9.5%— | 90+0.1%— | 90+99.5%— | 90—— | 90—— | 90—— | 45—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | 0.1−8.7%— | 0.0−5.0%— | 0.0−20.9%— | 0.0−23.3%— | 0.0*+20.0%— | 0.0−4.8%— | 0.0+38.7%— | 0.0+65.4%— | 0.0*+52.2%— | 0.0—— | 0.0—— | 0.0—— | 0.0*—— | |
| Share-based compensation | 20,696+275%— | 13,908+285%— | 6,782+257%— | 4.5+119%— | 1.3*−34.1%— | 3,614+189115%— | 1,899+100803%— | 2.0−25.7%— | 2.0*+21.2%— | 1.9*—— | 1.9*—— | 2.8—— | 1.6*—— | |
| Cash from operating activities | −96—— | −28*—— | −31*—— | −17—— | −19*—— | −20*—— | −25*—— | −22—— | −23*—— | −21r−21*—— | −17r−17*—— | −24—— | −14*—— | |
| Capital expenditure | −0.4—— | −0.1*—— | −0.2*—— | −0.0—— | −0.0*—— | −0.1*—— | −0.0*—— | −0.0—— | −0.0*—— | −0.1*—— | −0.2*—— | −0.0—— | −0.2*—— | |
| Cash from investing activities | −0.4—— | −0.1*—— | −0.2*—— | −0.0—— | −0.0*—— | −0.1*—— | −0.0*—— | −0.0—— | −0.0*—— | −0.1*—— | −0.2*—— | −0.0—— | −0.2*—— | |
| Shares issued | — | — | — | — | 0*—— | 0*—— | 0*—— | 0−100%— | 0*−100%— | 0*—— | 0*—— | 0.2—— | 0.6*—— | |
| Cash from financing activities | 194+196%— | 5.3*—— | 0.1*−99.8%— | 189—— | 0.1*−23.4%— | 0*—— | 66*—— | 0−100%— | 0.1*−87.3%— | 0*—— | 0*—— | 74—— | 0.6*—— | |
| Exchange-rate effect on cash | −1.0−1006%— | 0.0*+44.8%— | −0.4*−402%— | −0.2−142%— | −0.4*—— | 0.0*−86.7%— | 0.1*—— | 0.5+164%— | −0.5*−190%— | 0.2r0.2*—— | −0.4r−0.4*—— | 0.2—— | 0.6*—— | |
| Change in cash | 97—— | −23*—— | −32*−177%— | 171—— | −20*—— | −20*—— | 41*—— | −21−142%— | −23*—— | −21*—— | −18*—— | 51—— | −13*—— | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Where Immunic, Inc. operates: 2 countries#
Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue. 2 subsidiaries on file.
| Country | Presence | Revenue there |
|---|---|---|
| 🇺🇸 USA | Headquarters1 office1 subsidiary | — |
| 🇩🇪 Germany | 1 subsidiary | — |
Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided
Events at Immunic, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Delisting notice 2 · Directors and officers 13 · Material agreement 2 · Unregistered share sale 1 · Shareholder rights changed 1 · Bylaws or fiscal year changed 1 · Shareholder vote 3 · Results announced 5
| Filed | What happened | Filing |
|---|---|---|
| Directors and officers | 8-K | |
| Directors and officersResults announced | 8-K | |
| Directors and officers | 8-K | |
| Directors and officersShareholder vote | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Shareholder rights changedBylaws or fiscal year changed | 8-K | |
| Shareholder vote | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Directors and officersMaterial agreementUnregistered share sale | 8-K | |
| Delisting notice | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Delisting notice | 8-K | |
| Directors and officersShareholder vote | 8-K | |
| Material agreement | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Sep 11, 2026
Acquisitions and funding#
5 private funding rounds before listing
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Feb 2026 | $200 M | Private placement after listing | $50 to $250 million | 43 | equity, options | SEC |
| Jan 2024 | $80 M | Private placement after listing | $50 to $250 million | 19 | equity, options | SEC |
| Oct 2022 | $60 M | Private placement after listing | $50 to $250 million | 14 | equity, options | SEC |
| Jan 2014 | $14 M | No. 5 | $10 to $50 million | 37 | equity | SEC |
| Feb 2013 | $32 M | No. 4 | $10 to $50 million | 62 | equity | SEC |
| Sep 2012 | $86 M | No. 3 | $50 to $250 million | 40 | equity, options | SEC |
| May 2012 | $3 M | No. 2 | $2 to $10 million | 1 | debt, options | SEC |
| May 2011 | $23 M | No. 1 | $10 to $50 million | 51 | equity, options | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
From US state WARN notices and SEC 8-K restructuring filings, newest first.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2018 | · | · | · | · | · | · | · | · | 85 | · | · | · | 85 |
| 2015 | · | · | · | · | · | · | · | 32 | · | · | · | · | 32 |
| Announced | People | Kind | Where | Source |
|---|---|---|---|---|
| 85 people | Restructuring planSEC 8-K | “(the “Company”) began notifying approximately 85 employees whose employment will be terminated on September 14, 2018.” | Filing | |
| 32 people | Restructuring planSEC 8-K | “The plan is expected to include a workforce reduction in force of 32 people.” | Filing |
Source: State WARN notices and SEC 8-K item 2.05
How Immunic, Inc. compares in Biotechnology
- Market cap$121 M · higher than 39% of 726
- FCF yield-71.1% · higher than 16% of 449
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Immunic, Inc.🇺🇸 | $121 M | — | — | — |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Oct 28, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, GLEIF register; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Immunic, Inc.? Verify and update this profile — free
Show Immunic, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.